



Review

# MicroRNA Regulation of Epithelial to Mesenchymal Transition

Mohammed L. Abba <sup>†</sup>, Nitin Patil <sup>†</sup>, Jörg Hendrik Leupold and Heike Allgayer <sup>\*</sup>

Received: 23 November 2015; Accepted: 5 January 2016; Published: 14 January 2016

Academic Editors: David A. Brenner, Tatiana Kisseleva and Jonas Fuxe

Department of Experimental Surgery, Center for Biomedicine and Medical Technology Mannheim (CBTM), Medical Faculty Mannheim, Ruprecht Karl University of Heidelberg, Ludolf-Krehl-Str. 6, 68135 Mannheim, Germany; Mohammed.Abba@medma.uni-heidelberg.de (M.L.A.); Nitin.Patil@medma.uni-heidelberg.de (N.P.); joerg.leupold@medma.uni-heidelberg.de (J.H.L.)

<sup>\*</sup> Correspondence: heike.allgayer@medma.uni-heidelberg.de; Tel.: +49-621-383-6876; Fax: +49-621-383-6878

<sup>†</sup> Contributed equally and share first authorship.

**Abstract:** Epithelial to mesenchymal transition (EMT) is a central regulatory program that is similar in many aspects to several steps of embryonic morphogenesis. In addition to its physiological role in tissue repair and wound healing, EMT contributes to chemo resistance, metastatic dissemination and fibrosis, amongst others. Classically, the morphological change from epithelial to mesenchymal phenotype is characterized by the appearance or loss of a group of proteins which have come to be recognized as markers of the EMT process. As with all proteins, these molecules are controlled at the transcriptional and translational level by transcription factors and microRNAs, respectively. A group of developmental transcription factors form the backbone of the EMT cascade and a large body of evidence shows that microRNAs are heavily involved in the successful coordination of mesenchymal transformation and *vice versa*, either by suppressing the expression of different groups of transcription factors, or otherwise acting as their functional mediators in orchestrating EMT. This article dissects the contribution of microRNAs to EMT and analyzes the molecular basis for their roles in this cellular process. Here, we emphasize their interaction with core transcription factors like the zinc finger enhancer (E)-box binding homeobox (ZEB), Snail and Twist families as well as some pluripotency transcription factors.

**Keywords:** microRNAs; MET; cancer; EMT; transcription factor


## 1. Epithelial to Mesenchymal Transition (EMT)

Epithelial cells are characterized by the presence of regular cell-cell contacts and adhesion to the surrounding cellular fabric, preventing the detachment of individual cells [1], as opposed to mesenchymal cells which do not form such intracellular contacts and have irregular cell shapes. As the term denotes, EMT is the transdifferentiation of polarized immotile epithelial cells to motile mesenchymal cells. The process encompasses a form of epithelial plasticity that is characterized by both morphological and molecular changes in epithelial cells [2–6].

Physiologically, the process of EMT occurs during embryonic development and during tissue repair, allowing for the differentiation of cells and remodeling of tissues; however, EMT is also integral to a number of pathological settings including fibrosis and cancer progression [7–10]. EMT is not a one-way street as a reversal of the process from a mesenchymal to an epithelial state; mesenchymal to epithelial transition (MET) occurs in many systems [11]. Moreover, EMT has also come to be recognized as not being an all or nothing phenomenon with epithelial and mesenchymal states at opposite poles, but rather as a spectrum with a hybrid epithelial/mesenchymal intermediate [12–14]. Arguably, this intermediate state, also referred to as partial or incomplete EMT, is seen more as the norm than the

exception and represents the EMT phenotype observed during collective migration of neural crest cells in amphibians [15], in *Drosophila* metamorphosis [16], and at the tumor invasive fronts of several cancers [17–19], to mention a few examples.

Although the underlying molecular mechanisms that define the pathological and physiological activities of EMT in distinct cellular contexts likely intersect, the diversity of biological outcomes engendered by EMT is nonetheless highly specialized [20,21]. In cancer, particularly, EMT enables epithelial cells to acquire the abilities to invade, resist apoptosis, and to disseminate into distant organs [22–26] (Figure 1). EMT is activated and perpetuated in response to appropriate paracrine signals emanating principally from stromal cells comprising fibroblasts, myofibroblasts and mesenchymal stem cells, amongst others. These stromal cells secrete an array of heterotypic signals that include growth factors like transforming growth factor (TGF)- $\beta$ , vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), epidermal growth factor (EGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) leading to the activation of signaling cascades driven by these molecules. Other important signaling cascades important in driving EMT include the Wnt, Notch, Sonic hedgehog pathways [24,27]). Importantly, the EMT-driven metastatic cascade often involves the coordinated interplay of a number of key players that act concertedly to drive tumor dissemination. Our group recently identified a novel network that combined a transcriptional repressor, a histone methyltransferase, an ubiquitin protein ligase and three miRNAs interacting together to foster metastasis [28].



**Figure 1.** Schematic representation of EMT de-regulating transcription factors and the major key players in the regulation of EMT (down regulation is shown by red downward arrows and up regulation by red upward arrows).

The molecular program that drives EMT is orchestrated primarily by a set of multivalently acting transcriptional factors, including zinc finger enhancer (E)-box binding homeobox 1, (ZEB1), survival of motor neuron protein interacting protein 1 (SIP1) [29–34], the zinc finger proteins, SNAI1 (SNAIL) and SNAI2 (SLUG) [30,35–38] as well as the twist-related protein 1 (TWIST1) [39]. These transcriptional regulators are expressed in various combinations in a number of malignant tumor types and have been shown in experimental models of carcinoma formation to be causally important for programming invasion and even metastasis, when ectopically expressed. Moreover, these transcription factors regulate one another as well as an overlapping set of target genes, with current evidence pinning their involvement in all steps of the invasion-metastasis cascade with the exception of metastatic colonization [40,41]. These transcription factors act to concertedly modulate a loss of adherens junctions, degrade the extracellular matrix and enhance cellular motility, almost always accompanied by the morphological transformation of cells to a spindle-like shape [37,42,43].

## 2. MicroRNAs

MicroRNAs (miRNAs, miRs), a large group of small non-coding RNAs, function by binding to the three prime untranslated region (3'UTR) of messenger RNA (mRNA) molecules, triggering the formation of a complex which, in mammals, results in posttranscriptional repression of the bound

mRNA, either by mRNA degradation or inhibition of mRNA protein translation. Overwhelming evidence in literature, as well as experimental studies, have shown miRNAs to be potent regulators of normal cellular physiology. Their effect has been demonstrated in virtually all organ systems and cell types, and their aberrant expression is implicit to several pathological processes and diseases including inflammation, apoptosis, heart failure, Alzheimer's disease, osteoporosis, diabetes and cancer [44–60]. Their short nucleotides (nt) sequence (22 nt) and even shorter seed sequence (~7 nt) that is required for target binding makes miRNAs “adulterous” molecules, potentially capable of regulating several mRNAs simultaneously [61–63]. In this context, particular miRNAs /miRNA families have been found to singularly regulate cellular networks and signaling cascades, making them “master regulators” of these processes [28,64–69].

Expectedly, miRNAs also regulate EMT. They do so by interacting with the pool of critical molecules that are involved in engineering EMT, modulating their expression and consequently, their function [2,61–65,70–75]. The regulated molecules are many and varied, as EMT itself is complex, and they include mesenchymal proteins, N-cadherin, vimentin, fibronectin, the cytoskeletal and adherens junction proteins including E-cadherin, cytokeratin and occludin but, importantly, the transcription factors that are at the core of the EMT process [76]. This review focusses on the miRNA regulation of the transcription factors involved in EMT (Figure 1).

### 3. Transcription Factors in EMT Regulation

#### 3.1. The ZEB Family

The zinc finger E-box binding homeobox (ZEB) family comprises two members, ZEB1 and ZEB2 (also commonly known as smad interacting protein 1 (SIP1)). Their genes are located on the short arms of chromosomes 10 and 2, respectively, and both encode zinc finger transcription factors. These zinc finger proteins are characterized by the presence of two zinc finger clusters at each end of a central homeodomain. ZEB factors also contain multiple independent domains which interact with other transcriptional regulators [11,77–79]. ZEB1 and ZEB2 have overlapping, but still distinct, patterns of expression, and they trigger EMT through a combination of repression of epithelial and activation of mesenchymal proteins [2,37,70,79–82]. Both ZEB factors repress E-cadherin, tight junction protein 3 (TJP3), claudin 4, plakophilin 2, desmoplakin and connexins 26 and 31 [83–86]. Similarly, both proteins enhance vimentin, N-cadherin and matrix metalloproteinases (MMPs)-1 and -2. ZEB1 also suppresses crumbs 3, lethal giant larvae homolog 2 (LLGL2) and plakophilin 3 [78,87–90]. By being able to suppress a variety of cell junction type proteins as well as foster mesenchymal properties, ZEB proteins are powerful modulators of EMT.

The miR-200 family, made up of five members, miRs-200a, -200b, -200c, -429, and -141, plays a pivotal role in the regulation of both ZEB transcription factors. A number of reports, all published within weeks of each other, concurred and confirmed the significant role that the miR-200 family members played in maintaining the epithelial phenotype as a result of keeping the ZEB transcription factors in check [91–94].

In the first of these studies, the expression of 207 miRNAs in the 60 cell lines of the National Cancer Institute's drug screening panel (NCI60), subcategorized into cell lines with epithelial and mesenchymal phenotypes, identified the miR-200 family as a strong marker for cells that express E-cadherin but lack expression of vimentin [94]. They found miR-200 to directly target the mRNA of the E-cadherin transcriptional repressors ZEB1 and ZEB2 [94]. Korpala and colleagues obtained similar results using NMuMG murine mammary gland epithelial cells induced to undergo EMT with transforming growth factor beta 1 (TGF $\beta$ ) [93]. Using a slightly different method for EMT induction, Gregory *et al.* delineated the miRNA profiles of wild type canine MDCK (epithelial) and tyrosine phosphatase, non-receptor type 14 (PTPN14) stably transfected MDCK (mesenchymal) cells and observed a significant down regulation of all miR-200 family members, with subsequent 3'UTR luciferase assays, mRNA and protein quantification all showing a significant down regulation of the

ZEB proteins, especially upon transfection with miRs-200a and -b. [92]. An extra layer of intricacy was added to the equation when ZEB1 was found to directly suppress transcription of miR-141 and miR-200c, orchestrating a miRNA-mediated double negative feedback loop that stabilized EMT and promoted cancer cell invasion [91]. A myriad of reports have since then validated and re-validated the relationship between the miR-200 family and the ZEB transcription factors in different cell lines, disease types and experimental conditions. Moreover, a cocktail of miRNAs sometimes act together to reinforce the EMT phenotype, a prominent example being the synergistic effects of miR-218 and miR-200 in the regulation of ZEB2 [28].

A higher switch for the activation of the miR-200 family was unraveled when the tumor suppressor p53 was identified as a potent transactivator of a number of miRNAs that included the miR-200 and miR-192 families [95]. Subsequently, p53 was shown to suppress EMT by repressing the expression of ZEB1 and ZEB2. Additionally, the miR-192 family members also repressed ZEB2 expression [95]. Furthermore, miR-130b, another miRNA regulated by p53 also impacts EMT, but in this case, acting via ZEB1. Dong and colleagues were able to show that ectopic expression of p53 mutants repressed the expression of miR-130b and triggered ZEB1-dependent EMT and cancer cell invasion [96]. Loss of an endogenous p53 mutation in endometrial cancer cells increased the expression of miR-130b, attenuating the expression of ZEB1 and subsequently enhancing an epithelial phenotype [96].

Other miRNAs implicated to interact with ZEB transcription factors include miR-139-5p which was found to interact with both factors in hepatocellular carcinoma (HCC), and its suppression promoted EMT, migration, and invasion in Hep3B and SMMC7721 cells [97]. In breast cancer cells, miR-205 was also discovered to directly target ZEB1 and ZEB2; in this case, however, the polycomb ring finger protein 2 (Me1-18) was found to increase miR-205 transcription through the inhibition of DNA methyltransferase-mediated DNA methylation of the miR-205 promoter [98]. Interestingly, miR-205 was also identified as a very significantly upregulated miRNA in esophageal squamous cell carcinoma (ESCC) affecting cell migration and invasion and also targeting ZEB2, but contrary to the norm, was found to be elevated in these tumor cells, although the authors still project it as a tumor suppressor miRNA [99].

Some miRNAs which modulate EMT have been found to interact with just one of the ZEB transcription factors as highlighted below. For instance, in bladder cancer, the expression miR-23b was used to distinguish normal and bladder cancer tissues and high expression of this miR-23b correlated positively with higher overall survival of bladder cancer patients [100]. ZEB1 was found to be the direct target of miR-23b and responsible for promoting bladder cancer cell migration and invasion [100].

*In vitro* assays showed ZEB1 as a new direct target of miR-150 and that miR-150 induced mesenchymal–epithelial transition (MET). MET-like changes in TE-8 ESCC cells mediated through ZEB1 degradation were able to inhibit tumorigenicity and tumor growth in a mouse xenograft model [101]. Moreover, miR-150 expression was significantly lower in cancer tissues compared to adjacent non-cancerous tissues and correlated with tumor size, lymph node metastasis, lymphatic invasion, venous invasion, clinical staging, and poor prognosis [101]. Still, miR-150 has been reported to also be downregulated in human epithelial ovarian cancer (EOC) tissues and patients' serum compared to normal controls, and ectopic expression of miR-150 could efficiently inhibit cell proliferation, invasion and metastasis by suppressing the expression of ZEB1 [102].

In an analysis of 71 colorectal cancer patients, miR-147 was identified as highly negatively-correlated with an EMT gene expression signature score and postulated to reverse EMT (MET). MiR-147 was found to primarily act by increasing the expression of cadherin type 1 (CDH1) and decreasing that of ZEB1, which it targets directly, resulting in the inhibition of cell motility and invasion. Additionally, miR-147 was able to dramatically reverse the native drug resistance of the HCT116 colon cancer cell line to Gefitinib [103].

Qu and colleagues discovered that miR-33b expression was dramatically decreased in lung adenocarcinoma cell lines and tissues, and this reduced expression was associated with tumor lymph

node metastasis mediated in part by the binding of miR-33b to the ZEB1 3'UTR region inhibiting ZEB1 expression [104].

Using a strategy that included a red fluorescent promoter reporter gene carrying the vimentin promoter together with additional morphological experiments, Yanaka and colleagues screened a 328-miRNA library in search of EMT inducing miRNAs and identified miR-544a as the most potent in gastric cancer cells. They demonstrated that the overexpression of miR-544a induced the expression of ZEB1, but also that of vimentin, and SNAIL1, while reducing CDH1 expression accompanied by an EMT phenotype. Subsequently, they showed that the reduction of CDH1 and AXIN2 by miR-544a also activated the wingless (WNT) signaling pathway by stabilizing  $\beta$ -catenin in the nucleus [105].

The tumor suppressor p21 functions downstream of p53 and has been shown to directly induce the transcription of certain EMT miRNAs. For example, in investigating if p21 was involved in EMT, one group sequenced and compared RNA reads from isogenic p21<sup>(+/+)</sup> and p21<sup>(-/-)</sup> cells and identified the miR-183-96-182 cluster, in addition to the well documented miR-200 family, to be downregulated in p21-deficient cells. They found that miR-183 and miR-96 repressed common targets that included ZEB1, as well as SLUG, integrin beta 1 (ITGB1), and Kruppel-like factor 4 (KLF4), and the restoration of miR-183, or miR-96 in p21<sup>(-/-)</sup> cells inhibited EMT, cell migration, and invasion. Interestingly, they found that p21 forms a complex with ZEB1 at the miR-183-96-182 cluster promoter to inhibit transcriptional repression of the cluster by ZEB1 [106].

The rate of mRNA decay is determined by *cis*-acting sequence elements contained within individual mRNAs that serve as binding sites for *trans*-acting factors that may positively or negatively impact the mRNA degradation process [107]. One of the best characterized *trans*-acting factors is the heterogeneous nuclear ribonucleoprotein D (HNRED) or AUF1 family of proteins, which bind to, and stabilize, certain mRNAs. Al-Khalaf and Aboussekhra discovered that AUF1 binds the 3'UTR of the ZEB1 mRNA and reduces its turnover. Furthermore, they found that miR-141 and miR-146b-5p were able to bind the 3'UTR of AUF1, leading to its down-regulation and in the process positively enhancing the epithelial phenotype [108].


Other miRNAs that interact with ZEB1 include miR-101, which was found to significantly inhibit the TGF- $\beta$ 1-induced EMT in hepatocytes [109]. Individual examples pertaining to ZEB2 include, for example, miR-153, which was shown to directly target ZEB2 in human EOC in the process suppressing EMT as well as invasion [110]. Others include miR-338-3p which was also discovered to inhibit migration and invasion of gastric cancer cells *in vitro* by interacting with ZEB2 together with the metastasis-associated in colon cancer-1 (MACC1) mRNA [111]. In bladder cancer, miR-145 was found to also regulate ZEB2, but, interestingly, the long non-coding RNA taurine up-regulated 1 (TUG1) was found to modulate the levels of miR-145 by acting as a competing endogenous RNA (ceRNA) for miR-145 [112]. This miRNA was found to be further active in prostate cancer cells, where it was found to limit invasion, migration, EMT, and the stemness of prostate cancer cells via the repression of ZEB2. Remarkably, ZEB2 was also found to directly repress the transcription of miR-145, establishing a double-negative feedback loop between ZEB2 and miR-145 with strong implications for prostate cancer metastasis [113].

In colorectal cancer, miR-132 was also found to be a relevant mediator of EMT as a result of its targeting of ZEB2, and was found to be of added prognostic value clinically, as patients with low expression of miR-132 tended to have worse disease-free survival than patients with high expression of miR-132 [114]. The mechanistic effects of miR-132 in EMT were also observed in human non-small cell lung cancer (NSCLC) where ZEB2 was also the major target [115].

Still, miR-138 was identified as another regulator of ZEB2. Working on head and neck squamous cell carcinoma cell lines, Liu and colleagues demonstrated that miR-138 regulated EMT not only by targeting ZEB2 but also via the direct targeting of vimentin mRNA and enhancer of zeste homologue 2 (EZH2), an epigenetic regulator which modulates the silencing of E-cadherin [116].

As cellular proteins, ZEB transcription factors are also transactivated by other transcription factors; for instance, ZEB2 is regulated by the GATA family transcriptional repressor tricho-rhino-phalangeal

syndrome type 1 (TRPS1). TRPS1 is directly regulated by miR-221 and miR-222, and the expression of these two miRs was found to induce EMT by decreasing the expression of epithelial-specific genes and enhancing those of mesenchymal-specific genes, accompanied by increased cell migration and invasion [117,118]. This example underscores the intricacy of miRNA regulation of EMT (Figure 2).



**Figure 2.** Overview of significant miRNAs involved in EMT regulation. This is specific to transcription factors only and includes microRNAs targeting transcription factors and microRNAs enhanced or repressed by transcription factor activity. An up-regulation/activation is shown by green arrows and translational/transcriptional repression, or -inhibition by red truncated lines.

### 3.2. The Snail Family (*Snai1*, *Snai2* and *Snai3*)

The Snail family of zinc-finger transcription factors comprise SNAIL1 (often designated as SNAIL), SNAIL2 (also known as SLUG), and SNAIL3 (also known as SMUC). They occupy a central role in EMT, as well as embryonal morphogenesis [11,81,119–122]. All three transcription factors contain a single C-terminal zinc finger cluster that binds to E-boxes in the regulatory regions of target genes and an N-terminal SNAG (Snail/Gfi) domain that is important for repression in mammalian cells [123]. Upon binding to the E-box, Snail family members act as transcriptional repressors and recognize a core consensus binding motif that is identical to that recognized by the basic helix-loop-helix (bHLH) transcription factors [124].

SNAIL1 and SNAIL2 are the dominant players orchestrating EMT, and there is little literature about SNAIL3 and EMT. Unlike the ZEB family of transcription factors, SNAIL1 and SNAIL2 appear to have no overlapping roles in EMT as evidenced by the non-overlapping mRNA and miRNA clusters in both expression profiling types [125–127]. Nonetheless, Moreno-Bueno and colleagues in their attempt to elucidate mRNAs regulated by these factors identified collagen type V alpha 2 (COL5A2), moesin (MSN), TIMP metalloproteinase inhibitor 1 (TIMP1), serpin peptidase inhibitor, clade H (heat shock protein 47) member 1, (collagen binding protein 1) (SERPINH2), WAS/WASL interacting protein family member 1 (WASPIP), collagen type I alpha 2 (COL1A2), integrin alpha 5 (fibronectin receptor, alpha polypeptide) (ITGA5), caldesmon 1 (CALD1), serpin peptidase inhibitor clade E (nexin, plasminogen activator inhibitor type 1) member 1 (SERPINE1), collagen type III alpha 1 (COL3A1) and secreted protein acidic cysteine-rich (osteonectin) (SPARC) as commonly up-regulated and CDH1, secreted phosphoprotein 1 (SPP1), fibroblast growth factor binding protein 1 (FGFBP1), keratin 19 type I

(KRT19), tetraspanin 13 (TSPAN13), integrin beta 6 (ITGB6) as commonly downregulated by Snai1 and Snai2 [125].

Likewise, in the search for a core miRNA-EMT signature, Diaz-Martin *et al.* induced EMT in the canine epithelial MDCK cell line using the major EMT inducing transcription factors comprising the Snail, ZEB and Twist families, and lysyl oxidase-like 2 (LOXL2) individually followed by comparison of differentially regulated miRNAs across the board looking for commonalities [127–129]. Interestingly, they found members of the miR-200 family (miRs-200a, -200b, -200c, and -141), the miR-182 cluster (miRs-182, -183), miRs-18a, -18b, -486-5p, -486-3p, -31, -203, -100, -223, -99a, -375 and -133a as significantly deregulated in both situations. With the exception of miR-133a, whose expression was upregulated, all of the others were significantly downregulated by these transcription factors, including SNAI1 and SNAI2 [128,129]. This invariably not only indicates the central role that miRNAs in general, but that these miRNAs in particular, play in orchestrating EMT, but also to the fact that the core EMT machinery has an essential function in modulating miRNA expression, which makes them key effector molecules of the process (Figure 2).

A number of miRNAs have been documented to suppress the expression of SNAI1, with a few members of the miR-30 family showing significance. We found the expression of miR-30a to be inversely proportional to the invasive potential of various NSCLC cell lines correlating negatively with N-cadherin expression. Forced expression of miR-30a was able to alter cell morphology and suppress migration and invasion *in vitro*. This was paralleled by a repression of SNAI1, which was shown to be its direct target. Moreover, distant metastases to the lungs and liver were also suppressed in the presence of miR-30a in the chicken embryo model [130]. A similar phenomenon was demonstrated in hepatocellular carcinoma cell lines [131].

In their bid to elucidate the roles of p120 and E-cadherin in epithelial cell behavior, Kourtidis and colleagues showed that miR-30b was critical to the suppression of cell transforming markers that included Snai1, and the levels of miR-30b were regulated by pleckstrin homology domain containing family A member 7 (PLEKHA7), a p120 binding partner and an essential component of the cadherin complex [132]. A direct regulation was, however, not shown.

Another implicated miRNA group is the miR-34 family, a p53 regulated set. Kim and colleagues demonstrated that p53 loss-of-function or mutations promoted EMT by de-repressing SNAI1 protein expression and activity in multiple cancer cell lines. This was attributed to a decrease in miRNA-34 levels (miR-34a, miR-34b, and miR-34c), which suppressed SNAI1 directly by binding to a highly conserved region of its 3'UTR. The EMT effect was reinforced by the repression of other regulatory molecules, including  $\beta$ -catenin, LEF1, and Axin2 all of which contained miR-34 binding sites that were also sensitive to miR-34 dependent regulation [133].

Using a miRNA array in squamous cell carcinoma of the tongue cell lines whereby EMT was induced with TGF $\beta$  in one pair and the metastasis mesenchymal derivative of the primary cell line in the other, miR-153 was identified as significantly repressed in cells undergoing EMT. Ectopic expression of miR-153 in mesenchymal-like cells resulted in an epithelial transformation with decreased invasive abilities and to Snai1 suppression [134]. Similar results were obtained in gastric cancer where miR-153 was able to suppress migration and invasion by inhibiting SNAI1-induced EMT and also serve as an independent prognostic marker for predicting survival of gastric cancer patients [135] as was the case in pancreatic ductal adenocarcinoma (PDAC) [136].

Other significant miRNAs that impact SNAI1 expression include miR-199a which was found to increase the protein levels of claudin-1 in both TGF- $\beta$ 1-treated and -untreated cells in part by decreasing the protein level of SNAI1, a repressor of claudin-1 [137].

SNAI2 has its own unique set of regulating miRNAs that include miR-506 [138–140], miR-124 [141] and miR-181a [142]. Some miRNAs like miR-203 targets both SNAI1 and SNAI2 [143,144].

### 3.3. The Twist Family (TWIST1 and TWIST2)

The Twist family of basic helix-loop-helix transcription factors comprising TWIST1 (202 amino acids) and the smaller TWIST2 (also known as Dermo-1) (160 amino acids) play key roles in embryonic development. Both proteins have a conserved C-terminal Twist box interaction domain and basic Helix Loop Helix motif which is able to recognize E-box responsive elements (which binds to CANNTG region). Twist proteins act as either transcription repressors or activators, depending on the cellular context [145]. They are able to form homo- and heterodimers with each other [146–149] and to directly interact with a large set of transcription factors. The Twist factors are overexpressed in most in human cancers and in most cases correlate with high tumor grade, invasiveness, and metastasis [150–156].

As with the other transcription factors, several miRNAs are involved in the EMT modulating properties of the Twist proteins.

One of the upstream activators of TWIST is c-Src, which itself is activated by CD44 a cell-surface glycoprotein involved in cell-cell interactions, cell adhesion and migration. C-Src was found to increase Twist phosphorylation, promote its nuclear translocation and subsequently lead to the stimulation of miR-10b expression which is directly regulated by Twist. Inhibition the c-Src/TWIST axis causes down-regulation of Ras homolog gene family members RhoA/RhoC expression, impairment of tumor cell invasion and mitigation of the metastatic properties of MDA-MB-231 breast cancer cells [157]. Still, another group was able to demonstrate that miR-10b expression in breast cancer cells could be suppressed by wingless-type MMTV integration site family, member 1 (WNT1), inducible signaling pathway protein 2 (WISP2), a member of the WISP protein subfamily that acts by inhibition of TWIST1 expression [158].

In response to hypoxia, hypoxia inducible factor 1  $\alpha$  (HIF1 $\alpha$ ) is activated, leading to a surge in TWIST1 levels accompanied by the induction of miR-372/373 expression. The miR-372/373 targets reversion-inducing-cysteine-rich protein with kazal motifs (RECK) resulting in enhanced malignant cell behavior [159]. Taking a hint from similarly regulated homologues in mice, Yin and colleagues investigated a possible regulatory role of Twist1 in expression of the hsa-miR-199a/hsa-miR-214 cluster in human EOC cells and showed that TWIST1 induces the expression of the hsa-miR-199a/hsa-miR-214 cluster in these cells. Moreover, knowing that miR-199a directly regulates the expression of the inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta (IKK $\beta$ ), they proceeded to demonstrate that knocking down TWIST1 increased the levels of IKK $\beta$  significantly [160].

In dissecting the miRNAs that were differentially expressed in gastric cancer, Li and colleagues identified miR-223 to be overexpressed in metastatic gastric cancer cells only, and stimulated migration and invasion in non-metastatic gastric cancer cells. They discovered that miR-223 was induced by TWIST via binding to an E-box located in its core promoter, then binding to the 3'UTR of erythrocyte membrane protein band 4.1-like 3 (EPB41L3) and suppressing its translation [161].

Additional examples of miRNAs that are induced by TWIST1 include miR-181a [162,163] and miR-424, which were discovered to be upregulated early during a TWIST1 or SNAIL1-induced EMT, and cause the expression of mesenchymal genes without affecting epithelial genes [164].

As stated earlier, TWIST is also able to act as a transcriptional repressor, and such an effect was evident with miR-200 and miR-205. TWIST1 mRNA levels were found to be higher in cells with very low miR-200/miR-205 expression. Subsequently, an interaction with the promoters of miR-200/miR-205 was shown in HU609 cells, resulting in a stronger induction of gene expression than reported for the valid TWIST1 repression target, CDH1 [165].

In OSCC, let-7d expression was shown to negatively correlate with Twist and Snail expression in clinical samples as well as primary cultures. Scavenging endogenous let-7d in cultured cells with a sponge resulted in enhanced expression of TWIST, mesenchymal morphology, increased migration and colony formation [166]. In a much broader approach, Haga and Phinney decided to investigate the imprinted delta-like 1 homolog-deiodinase, iodothyronine, type III (DLK1-DIO3) region containing several miRNAs. They identified seven miRNAs, miRs-300, -382, -494, -495, -539, -543, and -544, located in this region that serve as tumor suppressors by cooperatively repressing an EMT signaling

network comprising TWIST1, BMI1 polycomb ring finger proto-oncogene, ZEB1/2, and the miR-200 family. Particularly, they were able to show that miRs-300, -539 and -543 significantly repressed TWIST1 [167]. Nairismägi *et al.* analyzed the translational regulation of TWIST1 using luciferase reporter assays in a variety of cell lines and found miR-145a-5p, miR-151-5p and miR-337-3p to be able to individually or in combination significantly repress Twist1 translation. They confirmed their findings with both exogenous and endogenous miRNAs. Twist suppression resulted in a decreased migratory potential of murine embryonic fibroblast cells [168,169]. The same group previously had looked at the *TWIST1* 3'UTR and identified miR-580 and two cytoplasmic polyadenylation elements, cytoplasmic polyadenylation element binding protein-1 and -2 (CPEB1, CPEB2), additional regulators of TWIST1 expression in MCF-10A cells [168].

A statistical analysis of 105 cases of primary human breast cancer demonstrated that decreased expression of miR-720 correlated with lymph node metastasis, and overexpression of this miRNA in breast cancer cells inhibited cell migration and invasion *in vitro* and *in vivo*. TWIST1 was identified as a direct functional target of miR-720 [170]. In addition, in HCC cells, miR-675 was found to mediate epithelial reprogramming through inhibition of TWIST1 expression, and miR-675 overexpression resulted in altered cellular morphology, reduced invasive potential, and increased anchorage-independent growth capacity and TWIST1 was identified as a direct target of this miR [171].

Other documented direct inhibitors of TWIST1 include miR-520d-5p [172], miR-137 [173], miR-33a [174,175], miR-186 [176] and miR-1-1 [177].

#### 3.4. Pluripotency Transcription Factors

Stemness and EMT have often been observed in the same context, and there are a number of reports which have shown that these two processes are intertwined. Robert Weinberg's lab demonstrated that it was possible to induce stem cell features in somatic immortalized human mammary epithelial cells (HMLEs) by overexpressing either TWIST or SNAI1 [178], with similar results being obtained by Morel and colleagues [179]. Conversely, the EMT-activator ZEB1 has been shown to promote tumorigenicity by repressing stemness-inhibiting miRNAs, miR-200c, miR-203 and miR-183 inclusive [180].

The transcription factors comprising SOX2, OCT-3/4, KLF4, NANOG and c-MYC form a core pluripotency network which governs the preservation of the pluripotent status quo, with OCT4, NANOG, and SOX2 shown to contribute to the reprogramming of somatic cells into an ESC-like state [61].

The SOX (SRY-related HMG-box) family of transcription factors is involved in the regulation of embryonic development, stemness and cell differentiation. A total of 20 Sox genes are present in the mammalian genome [181], and target gene selectivity by different Sox factors is realized through the differential affinity for particular flanking sequences next to consensus Sox sites, homo- or heterodimerization among Sox proteins, posttranslational modifications of Sox factors, or interaction with other cofactors [182–184]. The SOX transcription factors normally synergize with SNAI1 or SNAI2 in driving EMT and/ or cell invasion, and the prominent members which have been implicated in EMT include SOX2, SOX9 and SOX17 [185].

The Krüppel-like transcription factors are zinc finger proteins that activate and suppress target gene transcription. The family members share three highly conserved classical Cys2/His2 zinc fingers which are located at the carboxyl terminus of the protein and enable Klf proteins to bind to related GC- and CACCC-boxes of DNA. KLF transcription factors are involved in the regulation of many developmental processes [186,187]. KLF4 appears to be the only member implicit to EMT.

NANOG is a DNA binding homeobox transcription factor involved in embryonic stem cell proliferation, renewal, and pluripotency and is expressed in the founder cells of the early mouse embryo, being the reason why it was named after the mythological Celtic land of the ever young, Tir nan Og, by the scientists that first identified its function [188].

Despite the entangled relationship between EMT and the pluripotency transcription factors, most of the existing literature elucidates only indirect or supporting functions for these transcription factors in EMT. As such, the miRNAs which are either regulated by, or regulate, these transcription factors also affect EMT indirectly. For instance, in pancreatic ductal adenocarcinoma, the loss of doublecortin-like kinase1 (DLCK1) results in the enhanced expression of miR-145, let-7 and miR-200. Increased levels of miR-145 results in the decreased expression of OCT4, SOX2, NANOG, KLF4 as well as KRAS and RREB1, whereas the increase in miR-200 culminates in the decreased expression of VEGFR1, VEGFR2 and EMT-related transcription factors ZEB1, ZEB2, SNAIL and SLUG [189]. The same group went on to show that XMD8-92, a kinase inhibitor with anti-cancer activity, inhibited AsPC-1 cancer cell proliferation and tumor xenograft growth via the downregulation of DCLK1 and subsequently enhanced expression of several miRNAs, with the inclusion of miR-143/145 to those previously reported. The affected downstream targets remained the same [190]. Xia and colleagues were able to demonstrate a direct binding of miR-638 to the 3'UTR of SOX2 with resultant significant suppression of its expression that was associated with a repression of SNAIL1, fibronectin and vimentin as well as a concomitant increase in the expression of E-cadherin. It was not clear if SOX2 was responsible for the reversal of the EMT phenotype (MET), or whether miR-638 had other targets that were responsible for this observation [191].

By using ICG-001, a specific CREB-binding protein (CBP)/ $\beta$ -catenin antagonist in Epstein-Barr Virus (EBV) positive nasopharyngeal carcinoma, Chan *et al.* observed a reduction in the cancer-stem-cell-like population of cells that, amongst other outcomes, was associated with an increase in miR-145. They observed that the ectopic expression of miR-145 effectively repressed SOX2 (its direct target) protein expression and inhibited tumor sphere formation. ICG-001-treated cells manifested re-expression of E-cadherin and decreased expression of vimentin after seven days of treatment. In addition, in this case, no direct link between Sox2 and the EMT phenotype was demonstrated [192].

An additional example includes the identification of SOX2 as the direct target of miR-371-5p, whose own expression was influenced by SOX17. The SOX17/miR-371-5p/SOX2 axis demonstrated a significant role in the regulation of EMT (vimentin, N-cadherin, TWIST2 increased; E-cadherin suppressed), stemness and metastasis [193]. The regulation of EMT by miR-371-5p was attributed to modulation of Wnt/ $\beta$ -catenin signaling, as no direct relationship to SOX2 was evident [194].

### 3.5. Other Transcription Factors

Finally, there are a number of other transcription factors linked to EMT, where, however, the literature is thin. These factors also appear to be of significance in orchestrating EMT and include the zinc finger protein 281 (ZNF281) whose expression is induced by SNAIL1 and inhibited by miR-34a [195] and the paired-related homeobox protein 1 (PRRX1; PRX-1), a rather recent addition to the EMT inducers, which, unlike other EMT transcription factors, does not concur with the described induction of stem cell-like properties concomitant with Snail-, TWIST-, or ZEB-mediated mesenchymal transitions [196] and which is targeted by miR-124 [197]. Last but not least, a basic helix-loop-helix transcription factor, the transcription factor 4 (TCF4), is directly regulated by miR-155 [198].

## 4. Conclusions

MicroRNAs play crucial roles in EMT, either as effector molecules of the core transcription factors or as modulators of their expression. Judging by the amount of published data, some miRNAs stand out as arguably the master regulators of EMT, most prominently, at present, the miR-200 family. This is not to in any way undermine the significance of the other players, given, as we know, the cell type and context-associated function of most miRNAs. One of the most insightful overviews comes perhaps from the work of Diaz-Martin and colleagues who attempted to decode the core miRNA signature associated with EMT and made an excellent assemblage. Interestingly, newly identified molecules with transcriptional activity, most recently for example, PRRX1 that impact EMT, may prove in future to be as significant as those already known. It remains without question that newer roles will be

ascribed to the miRNAs already implicated in EMT or novel proteins will be added to the machinery that drives EMT.

**Acknowledgments:** H.A. was supported by Alfred Krupp von Bohlen und Halbach Foundation, Essen, Hella-Buehler-Foundation, Heidelberg, The Hector Foundation, Weinheim, Ingrid-zu-Solms Foundation, Frankfurt, Walter Schulz Foundation, Munich, the Deutsche Krebshilfe, Bonn (109558; together with MLA), the DKFZ-MOST German Israel Cooperation, Heidelberg (CA149), and the HIPO/POP-Initiative for Personalized Oncology, Heidelberg (H032 and H027; together with MLA and NP). H.A. and J.H.L. were supported by the Wilhelm Sander Foundation, Munich, Germany (2012.036.1).

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Cavey, M.; Lecuit, T. Molecular bases of cell-cell junctions stability and dynamics. *Cold Spring Harb. Perspect. Biol.* **2009**, *1*, a002998.
2. Zaravinos, A. The regulatory role of micrnas in emt and cancer. *J. Oncol.* **2015**, *2015*, 865816.
3. Tam, W.L.; Weinberg, R.A. The epigenetics of epithelial-mesenchymal plasticity in cancer. *Nat. Med.* **2013**, *19*, 1438–1449.
4. Liu, W.; Vivian, C.J.; Brinker, A.E.; Hampton, K.R.; Lianidou, E.; Welch, D.R. Microenvironmental influences on metastasis suppressor expression and function during a metastatic cell's journey. *Cancer Microenviron.* **2014**, *7*, 117–131.
5. De Craene, B.; Berx, G. Regulatory networks defining emt during cancer initiation and progression. *Nat. Rev. Cancer* **2013**, *13*, 97–110.
6. Bedi, U.; Mishra, V.K.; Wasilewski, D.; Scheel, C.; Johnsen, S.A. Epigenetic plasticity: A central regulator of epithelial-to-mesenchymal transition in cancer. *Oncotarget* **2014**, *5*, 2016–2029. [[CrossRef](#)] [[PubMed](#)]
7. Demirkan, B. The roles of epithelial-to-mesenchymal transition (emt) and mesenchymal-to-epithelial transition (met) in breast cancer bone metastasis: Potential targets for prevention and treatment. *J. Clin. Med.* **2013**, *2*, 264–282. [[CrossRef](#)] [[PubMed](#)]
8. Corallino, S.; Malabarba, M.G.; Zobel, M.; Di Fiore, P.P.; Scita, G. Epithelial-to-mesenchymal plasticity harnesses endocytic circuitries. *Front. Oncol.* **2015**, *5*, 45. [[CrossRef](#)] [[PubMed](#)]
9. Chou, Y.S.; Yang, M.H. Epithelial-mesenchymal transition-related factors in solid tumor and hematological malignancy. *J. Chin. Med. Assoc.* **2015**, *78*, 438–445. [[CrossRef](#)] [[PubMed](#)]
10. Cannito, S.; Novo, E.; di Bonzo, L.V.; Busletta, C.; Colombatto, S.; Parola, M. Epithelial-mesenchymal transition: From molecular mechanisms, redox regulation to implications in human health and disease. *Antioxid. Redox Signal* **2010**, *12*, 1383–1430. [[CrossRef](#)] [[PubMed](#)]
11. Lamouille, S.; Xu, J.; Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. *Nat. Rev. Mol. Cell Biol.* **2014**, *15*, 178–196. [[PubMed](#)]
12. Nieto, M.A. Epithelial plasticity: A common theme in embryonic and cancer cells. *Science* **2013**, *342*, 1234850. [[PubMed](#)]
13. Jolly, M.K.; Boareto, M.; Huang, B.; Jia, D.; Lu, M.; Ben-Jacob, E.; Onuchic, J.N.; Levine, H. Implications of the hybrid epithelial/mesenchymal phenotype in metastasis. *Front. Oncol.* **2015**, *5*, 155. [[CrossRef](#)] [[PubMed](#)]
14. Revenu, C.; Gilmour, D. Emt 2.0: Shaping epithelia through collective migration. *Curr. Opin. Genet. Dev.* **2009**, *19*, 338–342. [[CrossRef](#)] [[PubMed](#)]
15. Theveneau, E.; Marchant, L.; Kuriyama, S.; Gull, M.; Moepps, B.; Parsons, M.; Mayor, R. Collective chemotaxis requires contact-dependent cell polarity. *Dev. Cell* **2010**, *19*, 39–53. [[CrossRef](#)] [[PubMed](#)]
16. Ninov, N.; Chiarelli, D.A.; Martin-Blanco, E. Extrinsic and intrinsic mechanisms directing epithelial cell sheet replacement during drosophila metamorphosis. *Development* **2007**, *134*, 367–379. [[CrossRef](#)] [[PubMed](#)]
17. Nakashima, Y.; Yoshinaga, K.; Kitao, H.; Ando, K.; Kimura, Y.; Saeki, H.; Oki, E.; Morita, M.; Kakeji, Y.; Hirahashi, M.; *et al.* Podoplanin is expressed at the invasive front of esophageal squamous cell carcinomas and is involved in collective cell invasion. *Cancer Sci.* **2013**, *104*, 1718–1725. [[CrossRef](#)] [[PubMed](#)]
18. Su, S.; Liu, Q.; Chen, J.; Chen, J.; Chen, F.; He, C.; Huang, D.; Wu, W.; Lin, L.; Huang, W.; *et al.* A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. *Cancer Cell* **2014**, *25*, 605–620. [[CrossRef](#)] [[PubMed](#)]

19. Sarrio, D.; Rodriguez-Pinilla, S.M.; Hardisson, D.; Cano, A.; Moreno-Bueno, G.; Palacios, J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. *Cancer Res.* **2008**, *68*, 989–997. [[CrossRef](#)] [[PubMed](#)]
20. Kalluri, R.; Weinberg, R.A. The basics of epithelial-mesenchymal transition. *J. Clin. Investig.* **2009**, *119*, 1420–1428. [[CrossRef](#)] [[PubMed](#)]
21. Kalluri, R. Emt: When epithelial cells decide to become mesenchymal-like cells. *J. Clin. Investig.* **2009**, *119*, 1417–1419. [[CrossRef](#)] [[PubMed](#)]
22. Klymkowsky, M.W.; Savagner, P. Epithelial-mesenchymal transition: A cancer researcher's conceptual friend and foe. *Am. J. Pathol.* **2009**, *174*, 1588–1593. [[CrossRef](#)] [[PubMed](#)]
23. Polyak, K.; Weinberg, R.A. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. *Nat. Rev. Cancer* **2009**, *9*, 265–273. [[CrossRef](#)] [[PubMed](#)]
24. Thiery, J.P.; Acloque, H.; Huang, R.Y.; Nieto, M.A. Epithelial-mesenchymal transitions in development and disease. *Cell* **2009**, *139*, 871–890. [[CrossRef](#)] [[PubMed](#)]
25. Yilmaz, M.; Christofori, G. Emt, the cytoskeleton, and cancer cell invasion. *Cancer Metastasis Rev.* **2009**, *28*, 15–33. [[CrossRef](#)] [[PubMed](#)]
26. Barrallo-Gimeno, A.; Nieto, M.A. The snail genes as inducers of cell movement and survival: Implications in development and cancer. *Development* **2005**, *132*, 3151–3161. [[CrossRef](#)] [[PubMed](#)]
27. Ye, X.; Weinberg, R.A. Epithelial-mesenchymal plasticity: A central regulator of cancer progression. *Trends Cell Biol.* **2015**, *25*, 675–686. [[CrossRef](#)] [[PubMed](#)]
28. Mudduluru, G.; Abba, M.; Batliner, J.; Patil, N.; Scharp, M.; Lunavat, T.R.; Leupold, J.H.; Oleksiuk, O.; Juraeva, D.; Thiele, W.; *et al.* A systematic approach to defining the microRNA landscape in metastasis. *Cancer Res.* **2015**, *75*, 3010–3019. [[CrossRef](#)] [[PubMed](#)]
29. Aigner, K.; Dampier, B.; Descovich, L.; Mikula, M.; Sultan, A.; Schreiber, M.; Mikulits, W.; Brabletz, T.; Strand, D.; Obrist, P.; *et al.* The transcription factor zeb1 (deltaef1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. *Oncogene* **2007**, *26*, 6979–6988. [[CrossRef](#)] [[PubMed](#)]
30. Bolos, V.; Peinado, H.; Perez-Moreno, M.A.; Fraga, M.F.; Esteller, M.; Cano, A. The transcription factor slug represses e-cadherin expression and induces epithelial to mesenchymal transitions: A comparison with snail and e47 repressors. *J. Cell. Sci.* **2003**, *116*, 499–511. [[CrossRef](#)] [[PubMed](#)]
31. Grootclaes, M.L.; Frisch, S.M. Evidence for a function of ctbp in epithelial gene regulation and anoikis. *Oncogene* **2000**, *19*, 3823–3828. [[CrossRef](#)] [[PubMed](#)]
32. Hajra, K.M.; Fearon, E.R. Cadherin and catenin alterations in human cancer. *Genes Chromosom. Cancer* **2002**, *34*, 255–268. [[CrossRef](#)] [[PubMed](#)]
33. Hajra, K.M.; Chen, D.Y.; Fearon, E.R. The slug zinc-finger protein represses e-cadherin in breast cancer. *Cancer Res.* **2002**, *62*, 1613–1618. [[PubMed](#)]
34. Huber, M.A.; Kraut, N.; Beug, H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. *Curr. Opin. Cell. Biol.* **2005**, *17*, 548–558. [[CrossRef](#)] [[PubMed](#)]
35. Battle, E.; Sancho, E.; Franci, C.; Dominguez, D.; Monfar, M.; Baulida, J.; Garcia De Herreros, A. The transcription factor snail is a repressor of e-cadherin gene expression in epithelial tumour cells. *Nat. Cell. Biol.* **2000**, *2*, 84–89. [[CrossRef](#)] [[PubMed](#)]
36. Cano, A.; Perez-Moreno, M.A.; Rodrigo, I.; Locascio, A.; Blanco, M.J.; del Barrio, M.G.; Portillo, F.; Nieto, M.A. The transcription factor snail controls epithelial-mesenchymal transitions by repressing e-cadherin expression. *Nat. Cell. Biol.* **2000**, *2*, 76–83. [[CrossRef](#)] [[PubMed](#)]
37. Peinado, H.; Olmeda, D.; Cano, A. Snail, zeb and bhlh factors in tumour progression: An alliance against the epithelial phenotype? *Nat. Rev. Cancer* **2007**, *7*, 415–428. [[CrossRef](#)] [[PubMed](#)]
38. Yoshida, J.; Horiuchi, A.; Kikuchi, N.; Hayashi, A.; Osada, R.; Ohira, S.; Shiozawa, T.; Konishi, I. Changes in the expression of e-cadherin repressors, snail, slug, sip1, and twist, in the development and progression of ovarian carcinoma: The important role of snail in ovarian tumorigenesis and progression. *Med. Mol. Morphol.* **2009**, *42*, 82–91. [[CrossRef](#)] [[PubMed](#)]
39. Yang, J.; Mani, S.A.; Donaher, J.L.; Ramaswamy, S.; Itzykson, R.A.; Come, C.; Savagner, P.; Gitelman, I.; Richardson, A.; Weinberg, R.A. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. *Cell* **2004**, *117*, 927–939. [[CrossRef](#)] [[PubMed](#)]

40. Byles, V.; Zhu, L.; Lovaas, J.D.; Chmielewski, L.K.; Wang, J.; Faller, D.V.; Dai, Y. Sirt1 induces emt by cooperating with emt transcription factors and enhances prostate cancer cell migration and metastasis. *Oncogene* **2012**, *31*, 4619–4629. [[CrossRef](#)] [[PubMed](#)]
41. Dave, N.; Guaita-Esteruelas, S.; Gutarra, S.; Frias, A.; Beltran, M.; Peiro, S.; de Herreros, A.G. Functional cooperation between snail1 and twist in the regulation of zeb1 expression during epithelial to mesenchymal transition. *J. Biol. Chem.* **2011**, *286*, 12024–12032. [[CrossRef](#)] [[PubMed](#)]
42. Peinado, H.; Portillo, F.; Cano, A. Transcriptional regulation of cadherins during development and carcinogenesis. *Int. J. Dev. Biol.* **2004**, *48*, 365–375. [[CrossRef](#)] [[PubMed](#)]
43. Wheelock, M.J.; Shintani, Y.; Maeda, M.; Fukumoto, Y.; Johnson, K.R. Cadherin switching. *J. Cell. Sci.* **2008**, *121*, 727–735. [[CrossRef](#)] [[PubMed](#)]
44. Schickel, R.; Boyerinas, B.; Park, S.M.; Peter, M.E. Micronas: Key players in the immune system, differentiation, tumorigenesis and cell death. *Oncogene* **2008**, *27*, 5959–5974. [[CrossRef](#)] [[PubMed](#)]
45. Garofalo, M.; Croce, C.M. Micronas: Master regulators as potential therapeutics in cancer. *Annu. Rev. Pharmacol. Toxicol.* **2011**, *51*, 25–43. [[CrossRef](#)] [[PubMed](#)]
46. Bailey, S.G.; Sanchez-Elsner, T.; Stephanou, A.; Cragg, M.S.; Townsend, P.A. Regulating the genome surveillance system: Mirnas and the p53 super family. *Apoptosis* **2010**, *15*, 541–552. [[CrossRef](#)] [[PubMed](#)]
47. Baehrecke, E.H. Mirnas: Micro managers of programmed cell death. *Curr. Biol.* **2003**, *13*, R473–R475. [[CrossRef](#)]
48. Takeishi, Y. Biomarkers in heart failure. *Int. Heart J.* **2014**, *55*, 474–481. [[CrossRef](#)] [[PubMed](#)]
49. Stellato, C. Posttranscriptional gene regulation: Novel pathways for glucocorticoids' anti-inflammatory action. *Transl. Med. UniSa.* **2012**, *3*, 67–73. [[PubMed](#)]
50. States, J.C.; Srivastava, S.; Chen, Y.; Barchowsky, A. Arsenic and cardiovascular disease. *Toxicol. Sci.* **2009**, *107*, 312–323. [[CrossRef](#)] [[PubMed](#)]
51. Sinkovics, J.G. Molecular biology of oncogenic inflammatory processes. I. Non-oncogenic and oncogenic pathogens, intrinsic inflammatory reactions without pathogens, and microRNA/DNA interactions (review). *Int. J. Oncol.* **2012**, *40*, 305–349. [[CrossRef](#)] [[PubMed](#)]
52. Ranjha, R.; Paul, J. Micro-rnas in inflammatory diseases and as a link between inflammation and cancer. *Inflamm. Res.* **2013**, *62*, 343–355. [[CrossRef](#)] [[PubMed](#)]
53. Malemud, C.J. The discovery of novel experimental therapies for inflammatory arthritis. *Mediators Inflamm.* **2009**, *2009*, 698769. [[CrossRef](#)] [[PubMed](#)]
54. Lukiw, W.J.; Andreeva, T.V.; Grigorenko, A.P.; Rogaev, E.I. Studying micro rna function and dysfunction in alzheimer's disease. *Front Genet.* **2012**, *3*, 327. [[CrossRef](#)] [[PubMed](#)]
55. Kim, Y.; Eom, S.; Park, D.; Kim, H.; Jeoung, D. The hyaluronic acid-hdac3-mirna network in allergic inflammation. *Front Immunol.* **2015**, *6*, 210. [[CrossRef](#)] [[PubMed](#)]
56. Hamar, P. Role of regulatory micro rnas in type 2 diabetes mellitus-related inflammation. *Nucleic Acid Ther.* **2012**, *22*, 289–294. [[PubMed](#)]
57. Deb, R.; Kumar, A.; Chakraborty, S.; Verma, A.K.; Tiwari, R.; Dhama, K.; Singh, U.; Kumar, S. Trends in diagnosis and control of bovine mastitis: A review. *Pak. J. Biol. Sci.* **2013**, *16*, 1653–1661. [[CrossRef](#)] [[PubMed](#)]
58. Ather, M.H.; Siddiqui, T. The genetics of neuroendocrine prostate cancers: A review of current and emerging candidates. *Appl. Clin. Genet.* **2012**, *5*, 105–110. [[CrossRef](#)] [[PubMed](#)]
59. Alexander, M.; O'Connell, R.M. Noncoding rnas and chronic inflammation: Micro-managing the fire within. *Bioessays* **2015**, *37*, 1005–1015. [[CrossRef](#)] [[PubMed](#)]
60. Oleksiuk, O.; Abba, M.; Tezcan, K.C.; Schaufler, W.; Bestvater, F.; Patil, N.; Birk, U.; Hafner, M.; Altevogt, P.; Cremer, C.; *et al.* Single-molecule localization microscopy allows for the analysis of cancer metastasis-specific mirna distribution on the nanoscale. *Oncotarget* **2015**.
61. Utikal, J.; Abba, M.; Novak, D.; Moniuszko, M.; Allgayer, H. Function and significance of micrnas in benign and malignant human stem cells. *Semin. Cancer Biol.* **2015**, *35*, 200–211. [[CrossRef](#)] [[PubMed](#)]
62. Abba, M.; Patil, N.; Allgayer, H. Micrnas in the regulation of mmps and metastasis. *Cancers (Basel)* **2014**, *6*, 625–645. [[CrossRef](#)] [[PubMed](#)]
63. Abba, M.; Mudduluru, G.; Allgayer, H. Micrnas in cancer: Small molecules, big chances. *Anticancer Agents Med. Chem.* **2012**, *12*, 733–743. [[CrossRef](#)] [[PubMed](#)]
64. Mobley, A.K.; Braeuer, R.R.; Kamiya, T.; Shoshan, E.; Bar-Eli, M. Driving transcriptional regulators in melanoma metastasis. *Cancer Metastasis Rev.* **2012**, *31*, 621–632. [[CrossRef](#)] [[PubMed](#)]

65. Hoesel, B.; Schmid, J.A. The complexity of nf-kappab signaling in inflammation and cancer. *Mol. Cancer* **2013**, *12*, 86. [[CrossRef](#)] [[PubMed](#)]
66. Boldin, M.P.; Baltimore, D. Micrnas, new effectors and regulators of nf-kappab. *Immunol. Rev.* **2012**, *246*, 205–220. [[CrossRef](#)] [[PubMed](#)]
67. Liao, J.M.; Cao, B.; Zhou, X.; Lu, H. New insights into p53 functions through its target micrnas. *J. Mol. Cell. Biol.* **2014**, *6*, 206–213. [[CrossRef](#)] [[PubMed](#)]
68. Rokavec, M.; Li, H.; Jiang, L.; Hermeking, H. The p53/mir-34 axis in development and disease. *J. Mol. Cell. Biol.* **2014**, *6*, 214–230. [[CrossRef](#)] [[PubMed](#)]
69. Zhao, J.J.; Carrasco, R.D. Crosstalk between microrna30a/b/c/d/e-5p and the canonical wnt pathway: Implications for multiple myeloma therapy. *Cancer Res.* **2014**, *74*, 5351–5358. [[CrossRef](#)] [[PubMed](#)]
70. Zhang, J.; Ma, L. Microrna control of epithelial-mesenchymal transition and metastasis. *Cancer Metastasis Rev.* **2012**, *31*, 653–662. [[CrossRef](#)] [[PubMed](#)]
71. Romero-Cordoba, S.L.; Salido-Guadarrama, I.; Rodriguez-Dorantes, M.; Hidalgo-Miranda, A. Mirna biogenesis: Biological impact in the development of cancer. *Cancer Biol. Ther.* **2014**, *15*, 1444–1455. [[CrossRef](#)] [[PubMed](#)]
72. Hu, Y.; Tang, H. Micrnas regulate the epithelial to mesenchymal transition (emt) in cancer progression. *Microrna* **2014**, *3*, 108–117. [[CrossRef](#)] [[PubMed](#)]
73. Hao, J.; Zhang, Y.; Deng, M.; Ye, R.; Zhao, S.; Wang, Y.; Li, J.; Zhao, Z. Microrna control of epithelial-mesenchymal transition in cancer stem cells. *Int. J. Cancer.* **2014**, *135*, 1019–1027. [[CrossRef](#)] [[PubMed](#)]
74. Feng, X.; Wang, Z.; Fillmore, R.; Xi, Y. Mir-200, a new star mirna in human cancer. *Cancer Lett.* **2014**, *344*, 166–173. [[CrossRef](#)] [[PubMed](#)]
75. Rusek, A.M.; Abba, M.; Eljaszewicz, A.; Moniuszko, M.; Niklinski, J.; Allgayer, H. Microrna modulators of epigenetic regulation, the tumor microenvironment and the immune system in lung cancer. *Mol. Cancer* **2015**, *14*, 34. [[CrossRef](#)] [[PubMed](#)]
76. Mimeault, M.; Batra, S.K. Molecular biomarkers of cancer stem/progenitor cells associated with progression, metastases, and treatment resistance of aggressive cancers. *Cancer Epidemiol. Biomarkers Prev.* **2014**, *23*, 234–254. [[CrossRef](#)] [[PubMed](#)]
77. Zheng, H.; Kang, Y. Multilayer control of the emt master regulators. *Oncogene* **2014**, *33*, 1755–1763. [[CrossRef](#)] [[PubMed](#)]
78. Tania, M.; Khan, M.A.; Fu, J. Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. *Tumour Biol.* **2014**, *35*, 7335–7342. [[CrossRef](#)] [[PubMed](#)]
79. Son, H.; Moon, A. Epithelial-mesenchymal transition and cell invasion. *Toxicol. Res.* **2010**, *26*, 245–252. [[CrossRef](#)] [[PubMed](#)]
80. Vandewalle, C.; Van Roy, F.; Berx, G. The role of the zeb family of transcription factors in development and disease. *Cell. Mol. Life Sci.* **2009**, *66*, 773–787. [[CrossRef](#)] [[PubMed](#)]
81. Sanchez-Tillo, E.; Liu, Y.; de Barrios, O.; Siles, L.; Fanlo, L.; Cuatrecasas, M.; Darling, D.S.; Dean, D.C.; Castells, A.; Postigo, A. Emt-activating transcription factors in cancer: Beyond emt and tumor invasiveness. *Cell. Mol. Life Sci.* **2012**, *69*, 3429–3456. [[CrossRef](#)] [[PubMed](#)]
82. Hill, L.; Browne, G.; Tulchinsky, E. Zeb/mir-200 feedback loop: At the crossroads of signal transduction in cancer. *Int. J. Cancer* **2013**, *132*, 745–754. [[CrossRef](#)] [[PubMed](#)]
83. Lai-Cheong, J.E.; Arita, K.; McGrath, J.A. Genetic diseases of junctions. *J. Investig. Dermatol.* **2007**, *127*, 2713–2725. [[CrossRef](#)] [[PubMed](#)]
84. Schmidt, A.; Heid, H.W.; Schafer, S.; Nuber, U.A.; Zimbelmann, R.; Franke, W.W. Desmosomes and cytoskeletal architecture in epithelial differentiation: Cell type-specific plaque components and intermediate filament anchorage. *Eur. J. Cell. Biol.* **1994**, *65*, 229–245. [[PubMed](#)]
85. Tepass, U. Claudin complexities at the apical junctional complex. *Nat. Cell. Biol.* **2003**, *5*, 595–597. [[CrossRef](#)] [[PubMed](#)]
86. Katoh, M. Epithelial-mesenchymal transition in gastric cancer (review). *Int. J. Oncol.* **2005**, *27*, 1677–1683. [[PubMed](#)]
87. McConkey, D.J.; Choi, W.; Marquis, L.; Martin, F.; Williams, M.B.; Shah, J.; Svatek, R.; Das, A.; Adam, L.; Kamat, A.; *et al.* Role of epithelial-to-mesenchymal transition (emt) in drug sensitivity and metastasis in bladder cancer. *Cancer Metastasis Rev.* **2009**, *28*, 335–344. [[CrossRef](#)] [[PubMed](#)]

88. Yasumi, M.; Sakisaka, T.; Hoshino, T.; Kimura, T.; Sakamoto, Y.; Yamanaka, T.; Ohno, S.; Takai, Y. Direct binding of Igl2 to Ign during mitosis and its requirement for normal cell division. *J. Biol. Chem.* **2005**, *280*, 6761–6765. [[CrossRef](#)] [[PubMed](#)]
89. Musch, A.; Cohen, D.; Yeaman, C.; Nelson, W.J.; Rodriguez-Boulan, E.; Brennwald, P.J. Mammalian homolog of drosophila tumor suppressor lethal (2) giant larvae interacts with basolateral exocytic machinery in madin-darby canine kidney cells. *Mol. Biol. Cell* **2002**, *13*, 158–168. [[CrossRef](#)] [[PubMed](#)]
90. Elsum, I.A.; Martin, C.; Humbert, P.O. Scribble regulates an emt polarity pathway through modulation of mapk-erk signaling to mediate junction formation. *J. Cell. Sci.* **2013**, *126*, 3990–3999. [[CrossRef](#)] [[PubMed](#)]
91. Burk, U.; Schubert, J.; Wellner, U.; Schmalhofer, O.; Vincan, E.; Spaderna, S.; Brabletz, T. A reciprocal repression between zeb1 and members of the mir-200 family promotes emt and invasion in cancer cells. *EMBO Rep.* **2008**, *9*, 582–589. [[CrossRef](#)] [[PubMed](#)]
92. Gregory, P.A.; Bert, A.G.; Paterson, E.L.; Barry, S.C.; Tsykin, A.; Farshid, G.; Vadas, M.A.; Khew-Goodall, Y.; Goodall, G.J. The mir-200 family and mir-205 regulate epithelial to mesenchymal transition by targeting zeb1 and sip1. *Nat. Cell. Biol.* **2008**, *10*, 593–601. [[CrossRef](#)] [[PubMed](#)]
93. Korpala, M.; Lee, E.S.; Hu, G.; Kang, Y. The mir-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of e-cadherin transcriptional repressors zeb1 and zeb2. *J. Biol. Chem.* **2008**, *283*, 14910–14914. [[CrossRef](#)] [[PubMed](#)]
94. Park, S.M.; Gaur, A.B.; Lengyel, E.; Peter, M.E. The mir-200 family determines the epithelial phenotype of cancer cells by targeting the e-cadherin repressors zeb1 and zeb2. *Genes Dev.* **2008**, *22*, 894–907. [[CrossRef](#)] [[PubMed](#)]
95. Kim, T.; Veronese, A.; Pichiorri, F.; Lee, T.J.; Jeon, Y.J.; Volinia, S.; Pineau, P.; Marchio, A.; Palatini, J.; Suh, S.S.; *et al.* P53 regulates epithelial-mesenchymal transition through micrnas targeting zeb1 and zeb2. *J. Exp. Med.* **2011**, *208*, 875–883. [[CrossRef](#)] [[PubMed](#)]
96. Dong, P.; Karaayvaz, M.; Jia, N.; Kaneuchi, M.; Hamada, J.; Watari, H.; Sudo, S.; Ju, J.; Sakuragi, N. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the mir-130b-zeb1 axis. *Oncogene* **2013**, *32*, 3286–3295. [[CrossRef](#)] [[PubMed](#)]
97. Qiu, G.; Lin, Y.; Zhang, H.; Wu, D. Mir-139-5p inhibits epithelial-mesenchymal transition, migration and invasion of hepatocellular carcinoma cells by targeting zeb1 and zeb2. *Biochem. Biophys. Res. Commun.* **2015**, *463*, 315–321. [[CrossRef](#)] [[PubMed](#)]
98. Lee, J.Y.; Park, M.K.; Park, J.H.; Lee, H.J.; Shin, D.H.; Kang, Y.; Lee, C.H.; Kong, G. Loss of the polycomb protein mel-18 enhances the epithelial-mesenchymal transition by zeb1 and zeb2 expression through the downregulation of mir-205 in breast cancer. *Oncogene* **2014**, *33*, 1325–1335. [[CrossRef](#)] [[PubMed](#)]
99. Matsushima, K.; Isomoto, H.; Yamaguchi, N.; Inoue, N.; Machida, H.; Nakayama, T.; Hayashi, T.; Kunizaki, M.; Hidaka, S.; Nagayasu, T.; *et al.* Mirna-205 modulates cellular invasion and migration via regulating zinc finger e-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells. *J. Transl. Med.* **2011**, *9*, 30. [[CrossRef](#)] [[PubMed](#)]
100. Majid, S.; Dar, A.A.; Saini, S.; Deng, G.; Chang, I.; Greene, K.; Tanaka, Y.; Dahiya, R.; Yamamura, S. MicroRNA-23b functions as a tumor suppressor by regulating zeb1 in bladder cancer. *PLoS ONE* **2013**, *8*, e67686. [[CrossRef](#)] [[PubMed](#)]
101. Yokobori, T.; Suzuki, S.; Tanaka, N.; Inose, T.; Sohda, M.; Sano, A.; Sakai, M.; Nakajima, M.; Miyazaki, T.; Kato, H.; *et al.* Mir-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the emt inducer zeb1. *Cancer Sci.* **2013**, *104*, 48–54. [[CrossRef](#)] [[PubMed](#)]
102. Jin, M.; Yang, Z.; Ye, W.; Xu, H.; Hua, X. MicroRNA-150 predicts a favorable prognosis in patients with epithelial ovarian cancer, and inhibits cell invasion and metastasis by suppressing transcriptional repressor zeb1. *PLoS ONE* **2014**, *9*, e103965. [[CrossRef](#)] [[PubMed](#)]
103. Lee, C.G.; McCarthy, S.; Gruidl, M.; Timme, C.; Yeatman, T.J. MicroRNA-147 induces a mesenchymal-to-epithelial transition (met) and reverses egfr inhibitor resistance. *PLoS ONE* **2014**, *9*, e84597. [[CrossRef](#)] [[PubMed](#)]
104. Qu, J.; Li, M.; An, J.; Zhao, B.; Zhong, W.; Gu, Q.; Cao, L.; Yang, H.; Hu, C. MicroRNA-33b inhibits lung adenocarcinoma cell growth, invasion, and epithelial-mesenchymal transition by suppressing wnt/beta-catenin/zeb1 signaling. *Int. J. Oncol.* **2015**. [[CrossRef](#)] [[PubMed](#)]

105. Yanaka, Y.; Muramatsu, T.; Uetake, H.; Kozaki, K.I.; Inazawa, J. Mir-544a induces epithelial-mesenchymal transition through the activation of wnt signaling pathway in gastric cancer. *Carcinogenesis* **2015**. [[CrossRef](#)] [[PubMed](#)]
106. Li, X.L.; Hara, T.; Choi, Y.; Subramanian, M.; Francis, P.; Bilke, S.; Walker, R.L.; Pineda, M.; Zhu, Y.; Yang, Y.; *et al.* A p21-zeb1 complex inhibits epithelial-mesenchymal transition through the microrna 183-96-182 cluster. *Mol. Cell. Biol.* **2014**, *34*, 533–550. [[CrossRef](#)] [[PubMed](#)]
107. White, E.J.; Brewer, G.; Wilson, G.M. Post-transcriptional control of gene expression by auf1: Mechanisms, physiological targets, and regulation. *Biochim. Biophys. Acta.* **2013**, *1829*, 680–688. [[CrossRef](#)] [[PubMed](#)]
108. Al-Khalaf, H.H.; Aboussekhra, A. Microrna-141 and microrna-146b-5p inhibit the prometastatic mesenchymal characteristics through the rna-binding protein auf1 targeting the transcription factor zeb1 and the protein kinase akt. *J. Biol. Chem.* **2014**, *289*, 31433–31447. [[CrossRef](#)] [[PubMed](#)]
109. Zhao, S.; Zhang, Y.; Zheng, X.; Tu, X.; Li, H.; Chen, J.; Zang, Y.; Zhang, J. Loss of microrna-101 promotes epithelial to mesenchymal transition in hepatocytes. *J. Cell. Physiol.* **2015**, *230*, 2706–2717. [[CrossRef](#)] [[PubMed](#)]
110. Zhou, J.; Xie, M.; Shi, Y.; Luo, B.; Gong, G.; Li, J.; Wang, J.; Zhao, W.; Zi, Y.; Wu, X.; *et al.* Microrna-153 functions as a tumor suppressor by targeting set7 and zeb2 in ovarian cancer cells. *Oncol. Rep.* **2015**, *34*, 111–120. [[PubMed](#)]
111. Huang, N.; Wu, Z.; Lin, L.; Zhou, M.; Wang, L.; Ma, H.; Xia, J.; Bin, J.; Liao, Y.; Liao, W. Mir-338-3p inhibits epithelial-mesenchymal transition in gastric cancer cells by targeting zeb2 and macc1/met/akt signaling. *Oncotarget* **2015**, *6*, 15222–15234. [[CrossRef](#)] [[PubMed](#)]
112. Tan, J.; Qiu, K.; Li, M.; Liang, Y. Double-negative feedback loop between long non-coding rna tug1 and mir-145 promotes epithelial to mesenchymal transition and radioresistance in human bladder cancer cells. *FEBS Lett.* **2015**, *589*, 3175–3181. [[CrossRef](#)] [[PubMed](#)]
113. Ren, D.; Wang, M.; Guo, W.; Huang, S.; Wang, Z.; Zhao, X.; Du, H.; Song, L.; Peng, X. Double-negative feedback loop between zeb2 and mir-145 regulates epithelial-mesenchymal transition and stem cell properties in prostate cancer cells. *Cell Tissue Res.* **2014**, *358*, 763–778. [[CrossRef](#)] [[PubMed](#)]
114. Zheng, Y.B.; Luo, H.P.; Shi, Q.; Hao, Z.N.; Ding, Y.; Wang, Q.S.; Li, S.B.; Xiao, G.C.; Tong, S.L. Mir-132 inhibits colorectal cancer invasion and metastasis via directly targeting zeb2. *World J. Gastroenterol.* **2014**, *20*, 6515–6522. [[CrossRef](#)] [[PubMed](#)]
115. You, J.; Li, Y.; Fang, N.; Liu, B.; Zu, L.; Chang, R.; Li, X.; Zhou, Q. Mir-132 suppresses the migration and invasion of lung cancer cells via targeting the emt regulator zeb2. *PLoS ONE* **2014**, *9*, e91827. [[CrossRef](#)] [[PubMed](#)]
116. Liu, X.; Wang, C.; Chen, Z.; Jin, Y.; Wang, Y.; Kolokythas, A.; Dai, Y.; Zhou, X. Microrna-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. *Biochem. J.* **2011**, *440*, 23–31. [[CrossRef](#)] [[PubMed](#)]
117. Stinson, S.; Lackner, M.R.; Adai, A.T.; Yu, N.; Kim, H.J.; O'Brien, C.; Spoerke, J.; Jhunjhunwala, S.; Boyd, Z.; Januario, T.; *et al.* Mir-221/222 targeting of trichorhinophalangeal 1 (trps1) promotes epithelial-to-mesenchymal transition in breast cancer. *Sci. Signal* **2011**, *4*, pt5. [[PubMed](#)]
118. Stinson, S.; Lackner, M.R.; Adai, A.T.; Yu, N.; Kim, H.J.; O'Brien, C.; Spoerke, J.; Jhunjhunwala, S.; Boyd, Z.; Januario, T.; *et al.* Trps1 targeting by mir-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. *Sci. Signal* **2011**, *4*, ra41. [[PubMed](#)]
119. Wang, Y.; Zhou, B.P. Epithelial-mesenchymal transition—A hallmark of breast cancer metastasis. *Cancer Hallm.* **2013**, *1*, 38–49. [[CrossRef](#)] [[PubMed](#)]
120. Wang, Y.; Shi, J.; Chai, K.; Ying, X.; Zhou, B.P. The role of snail in emt and tumorigenesis. *Curr. Cancer Drug Targets* **2013**, *13*, 963–972. [[CrossRef](#)] [[PubMed](#)]
121. Lin, Y.; Dong, C.; Zhou, B.P. Epigenetic regulation of emt: The snail story. *Curr. Pharm. Des.* **2014**, *20*, 1698–1705. [[CrossRef](#)] [[PubMed](#)]
122. Baulida, J.; Garcia de Herreros, A. Snail1-driven plasticity of epithelial and mesenchymal cells sustains cancer malignancy. *Biochim. Biophys. Acta.* **2015**, *1856*, 55–61. [[CrossRef](#)] [[PubMed](#)]
123. Chiang, C.; Ayyanathan, K. Snail/gfi-1 (snag) family zinc finger proteins in transcription regulation, chromatin dynamics, cell signaling, development, and disease. *Cytokine Growth Factor. Rev.* **2013**, *24*, 123–131. [[CrossRef](#)] [[PubMed](#)]

124. Kataoka, H.; Murayama, T.; Yokode, M.; Mori, S.; Sano, H.; Ozaki, H.; Yokota, Y.; Nishikawa, S.; Kita, T. A novel snail-related transcription factor smuc regulates basic helix-loop-helix transcription factor activities via specific e-box motifs. *Nucleic Acids Res.* **2000**, *28*, 626–633. [[CrossRef](#)] [[PubMed](#)]
125. Moreno-Bueno, G.; Cubillo, E.; Sarrio, D.; Peinado, H.; Rodriguez-Pinilla, S.M.; Villa, S.; Bolos, V.; Jorda, M.; Fabra, A.; Portillo, F.; *et al.* Genetic profiling of epithelial cells expressing e-cadherin repressors reveals a distinct role for snail, slug, and e47 factors in epithelial-mesenchymal transition. *Cancer Res.* **2006**, *66*, 9543–9556. [[CrossRef](#)] [[PubMed](#)]
126. Olmeda, D.; Montes, A.; Moreno-Bueno, G.; Flores, J.M.; Portillo, F.; Cano, A. Snai1 and snai2 collaborate on tumor growth and metastasis properties of mouse skin carcinoma cell lines. *Oncogene* **2008**, *27*, 4690–4701. [[CrossRef](#)] [[PubMed](#)]
127. Diaz-Lopez, A.; Moreno-Bueno, G.; Cano, A. Role of microRNA in epithelial to mesenchymal transition and metastasis and clinical perspectives. *Cancer Manag. Res.* **2014**, *6*, 205–216. [[PubMed](#)]
128. Diaz-Lopez, A.; Diaz-Martin, J.; Moreno-Bueno, G.; Cuevas, E.P.; Santos, V.; Olmeda, D.; Portillo, F.; Palacios, J.; Cano, A. Zeb1 and snail1 engage mir-200f transcriptional and epigenetic regulation during emt. *J. Int. Cancer* **2015**, *136*, E62–E73. [[CrossRef](#)] [[PubMed](#)]
129. Diaz-Martin, J.; Diaz-Lopez, A.; Moreno-Bueno, G.; Castilla, M.A.; Rosa-Rosa, J.M.; Cano, A.; Palacios, J. A core microRNA signature associated with inducers of the epithelial-to-mesenchymal transition. *J. Pathol.* **2014**, *232*, 319–329. [[CrossRef](#)] [[PubMed](#)]
130. Kumarswamy, R.; Mudduluru, G.; Ceppi, P.; Muppala, S.; Kozlowski, M.; Niklinski, J.; Papotti, M.; Allgayer, H. MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting snail and is downregulated in non-small cell lung cancer. *J. Int. Cancer* **2012**, *130*, 2044–2053. [[CrossRef](#)] [[PubMed](#)]
131. Liu, Z.; Tu, K.; Liu, Q. Effects of microRNA-30a on migration, invasion and prognosis of hepatocellular carcinoma. *FEBS Lett.* **2014**, *588*, 3089–3097. [[CrossRef](#)] [[PubMed](#)]
132. Kourtidis, A.; Ngok, S.P.; Pulimeno, P.; Feathers, R.W.; Carpio, L.R.; Baker, T.R.; Carr, J.M.; Yan, I.K.; Borges, S.; Perez, E.A.; *et al.* Distinct e-cadherin-based complexes regulate cell behaviour through mirna processing or src and p120 catenin activity. *Nat. Cell. Biol.* **2015**, *17*, 1145–1157. [[CrossRef](#)] [[PubMed](#)]
133. Kim, N.H.; Kim, H.S.; Li, X.Y.; Lee, I.; Choi, H.S.; Kang, S.E.; Cha, S.Y.; Ryu, J.K.; Yoon, D.; Fearon, E.R.; *et al.* A p53/mirna-34 axis regulates snail1-dependent cancer cell epithelial-mesenchymal transition. *J. Cell Biol.* **2011**, *195*, 417–433. [[CrossRef](#)] [[PubMed](#)]
134. Xu, Q.; Sun, Q.; Zhang, J.; Yu, J.; Chen, W.; Zhang, Z. Downregulation of mir-153 contributes to epithelial-mesenchymal transition and tumor metastasis in human epithelial cancer. *Carcinogenesis* **2013**, *34*, 539–549. [[CrossRef](#)] [[PubMed](#)]
135. Zhang, Z.; Sun, J.; Bai, Z.; Li, H.; He, S.; Chen, R.; Che, X. MicroRNA-153 acts as a prognostic marker in gastric cancer and its role in cell migration and invasion. *Onco. Targets. Ther.* **2015**, *8*, 357–364. [[PubMed](#)]
136. Bai, Z.; Sun, J.; Wang, X.; Wang, H.; Pei, H.; Zhang, Z. MicroRNA-153 is a prognostic marker and inhibits cell migration and invasion by targeting snail in human pancreatic ductal adenocarcinoma. *Oncol. Rep.* **2015**, *34*, 595–602. [[CrossRef](#)] [[PubMed](#)]
137. Suzuki, T.; Mizutani, K.; Minami, A.; Nobutani, K.; Kurita, S.; Nagino, M.; Shimono, Y.; Takai, Y. Suppression of the tgf-beta1-induced protein expression of snail and n-cadherin by mir-199a. *Genes Cells* **2014**, *19*, 667–675. [[CrossRef](#)] [[PubMed](#)]
138. Yang, D.; Sun, Y.; Hu, L.; Zheng, H.; Ji, P.; Pecot, C.V.; Zhao, Y.; Reynolds, S.; Cheng, H.; Rupaimoole, R.; *et al.* Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. *Cancer Cell* **2013**, *23*, 186–199. [[CrossRef](#)] [[PubMed](#)]
139. Sun, Y.; Hu, L.; Zheng, H.; Bagnoli, M.; Guo, Y.; Rupaimoole, R.; Rodriguez-Aguayo, C.; Lopez-Berestein, G.; Ji, P.; Chen, K.; *et al.* Mir-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. *J. Pathol.* **2015**, *235*, 25–36. [[CrossRef](#)] [[PubMed](#)]
140. Arora, H.; Qureshi, R.; Park, W.Y. Mir-506 regulates epithelial mesenchymal transition in breast cancer cell lines. *PLoS ONE* **2013**, *8*, e64273. [[CrossRef](#)] [[PubMed](#)]
141. Roy-Chaudhuri, B.; Valdmanis, P.N.; Zhang, Y.; Wang, Q.; Luo, Q.J.; Kay, M.A. Regulation of microRNA-mediated gene silencing by microRNA precursors. *Nat. Struct. Mol. Biol.* **2014**, *21*, 825–832. [[CrossRef](#)] [[PubMed](#)]

142. He, Q.; Zhou, X.; Li, S.; Jin, Y.; Chen, Z.; Chen, D.; Cai, Y.; Liu, Z.; Zhao, T.; Wang, A. MicroRNA-181a suppresses salivary adenoid cystic carcinoma metastasis by targeting mapk-snai2 pathway. *Biochim. Biophys. Acta.* **2013**, *1830*, 5258–5266. [[CrossRef](#)] [[PubMed](#)]
143. Moes, M.; Le Behec, A.; Crespo, I.; Laurini, C.; Halavaty, A.; Vetter, G.; Del Sol, A.; Friederich, E. A novel network integrating a mirna-203/snai1 feedback loop which regulates epithelial to mesenchymal transition. *PLoS ONE* **2012**, *7*, e35440. [[CrossRef](#)] [[PubMed](#)]
144. Ding, X.; Park, S.I.; McCauley, L.K.; Wang, C.Y. Signaling between transforming growth factor beta (tgf-beta) and transcription factor snai2 represses expression of microRNA mir-203 to promote epithelial-mesenchymal transition and tumor metastasis. *J. Bio. Chem.* **2013**, *288*, 10241–10253. [[CrossRef](#)] [[PubMed](#)]
145. Hamamori, Y.; Sartorelli, V.; Ogryzko, V.; Puri, P.L.; Wu, H.Y.; Wang, J.Y.; Nakatani, Y.; Kedes, L. Regulation of histone acetyltransferases p300 and pcaf by the bhlh protein twist and adenoviral oncoprotein e1a. *Cell* **1999**, *96*, 405–413. [[CrossRef](#)]
146. Castanon, I.; Von Stetina, S.; Kass, J.; Baylies, M.K. Dimerization partners determine the activity of the twist bhlh protein during drosophila mesoderm development. *Development* **2001**, *128*, 3145–3159. [[PubMed](#)]
147. Firulli, B.A.; Krawchuk, D.; Centonze, V.E.; Vargesson, N.; Virshup, D.M.; Conway, S.J.; Cserjesi, P.; Laufer, E.; Firulli, A.B. Altered twist1 and hand2 dimerization is associated with saethre-hotzen syndrome and limb abnormalities. *Nat. Genet.* **2005**, *37*, 373–381. [[CrossRef](#)] [[PubMed](#)]
148. Connerney, J.; Andreeva, V.; Leshem, Y.; Muentener, C.; Mercado, M.A.; Spicer, D.B. Twist1 dimer selection regulates cranial suture patterning and fusion. *Dev. Dyn.* **2006**, *235*, 1345–1357. [[CrossRef](#)] [[PubMed](#)]
149. Connerney, J.; Andreeva, V.; Leshem, Y.; Mercado, M.A.; Dowell, K.; Yang, X.; Lindner, V.; Friesel, R.E.; Spicer, D.B. Twist1 homodimers enhance fgf responsiveness of the cranial sutures and promote suture closure. *Dev. Biol.* **2008**, *318*, 323–334. [[CrossRef](#)] [[PubMed](#)]
150. Yang, G.; Yuan, J.; Li, K. Emt transcription factors: Implication in osteosarcoma. *Med. Oncol.* **2013**, *30*, 697. [[CrossRef](#)] [[PubMed](#)]
151. Tseng, J.C.; Chen, H.F.; Wu, K.J. A twist tale of cancer metastasis and tumor angiogenesis. *Histol. Histopathol.* **2015**, *30*, 1283–1294. [[PubMed](#)]
152. Puisieux, A.; Valsesia-Wittmann, S.; Ansieau, S. A twist for survival and cancer progression. *Br. J. Cancer* **2006**, *94*, 13–17. [[CrossRef](#)] [[PubMed](#)]
153. Norozi, F.; Ahmadzadeh, A.; Shahjahani, M.; Shahrabi, S.; Saki, N. Twist as a new prognostic marker in hematological malignancies. *Clin. Transl. Oncol.* **2015**. [[CrossRef](#)] [[PubMed](#)]
154. Khan, M.A.; Chen, H.C.; Zhang, D.; Fu, J. Twist: A molecular target in cancer therapeutics. *Tumour Biol.* **2013**, *34*, 2497–2506. [[CrossRef](#)] [[PubMed](#)]
155. Karreth, F.; Tuveson, D.A. Twist induces an epithelial-mesenchymal transition to facilitate tumor metastasis. *Cancer Biol. Ther.* **2004**, *3*, 1058–1059. [[CrossRef](#)] [[PubMed](#)]
156. Hung, J.J.; Yang, M.H.; Hsu, H.S.; Hsu, W.H.; Liu, J.S.; Wu, K.J. Prognostic significance of hypoxia-inducible factor-1alpha, twist1 and snail expression in resectable non-small cell lung cancer. *Thorax* **2009**, *64*, 1082–1089. [[CrossRef](#)] [[PubMed](#)]
157. Bourguignon, L.Y.; Wong, G.; Earle, C.; Krueger, K.; Spevak, C.C. Hyaluronan-cd44 interaction promotes c-src-mediated twist signaling, microRNA-10b expression, and rhoa/rhoc up-regulation, leading to rho-kinase-associated cytoskeleton activation and breast tumor cell invasion. *J. Biol. Chem.* **2010**, *285*, 36721–36735. [[CrossRef](#)] [[PubMed](#)]
158. Haque, I.; Banerjee, S.; Mehta, S.; De, A.; Majumder, M.; Mayo, M.S.; Kambhampati, S.; Campbell, D.R.; Banerjee, S.K. Cysteine-rich 61-connective tissue growth factor-nephroblastoma-overexpressed 5 (ccn5)/wnt-1-induced signaling protein-2 (wisp-2) regulates microRNA-10b via hypoxia-inducible factor-1alpha-twist signaling networks in human breast cancer cells. *J. Biol. Chem.* **2011**, *286*, 43475–43485. [[CrossRef](#)] [[PubMed](#)]
159. Loayza-Puch, F.; Yoshida, Y.; Matsuzaki, T.; Takahashi, C.; Kitayama, H.; Noda, M. Hypoxia and ras-signaling pathways converge on, and cooperatively downregulate, the reck tumor-suppressor protein through microRNAs. *Oncogene* **2010**, *29*, 2638–2648. [[CrossRef](#)] [[PubMed](#)]
160. Yin, G.; Chen, R.; Alvero, A.B.; Fu, H.H.; Holmberg, J.; Glackin, C.; Rutherford, T.; Mor, G. Twisting stemness, inflammation and proliferation of epithelial ovarian cancer cells through mir199a2/214. *Oncogene* **2010**, *29*, 3545–3553. [[CrossRef](#)] [[PubMed](#)]

161. Li, X.; Zhang, Y.; Zhang, H.; Liu, X.; Gong, T.; Li, M.; Sun, L.; Ji, G.; Shi, Y.; Han, Z.; *et al.* Mirna-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor epb4113. *Mol. Cancer. Res.* **2011**, *9*, 824–833. [[CrossRef](#)] [[PubMed](#)]
162. Meng, F.; Glaser, S.S.; Francis, H.; DeMorrow, S.; Han, Y.; Passarini, J.D.; Stokes, A.; Cleary, J.P.; Liu, X.; Venter, J.; *et al.* Functional analysis of micrnas in human hepatocellular cancer stem cells. *J. Cell. Mol. Med.* **2012**, *16*, 160–173. [[CrossRef](#)] [[PubMed](#)]
163. Liu, M.; Wang, J.; Huang, H.; Hou, J.; Zhang, B.; Wang, A. Mir-181a-twist1 pathway in the chemoresistance of tongue squamous cell carcinoma. *Biochem. Biophys. Res. Commun.* **2013**, *441*, 364–370. [[CrossRef](#)] [[PubMed](#)]
164. Drasin, D.J.; Guarnieri, A.L.; Neelakantan, D.; Kim, J.; Cabrera, J.H.; Wang, C.A.; Zaberezhnyy, V.; Gasparini, P.; Cascione, L.; Huebner, K.; *et al.* Twist1-induced mir-424 reversibly drives mesenchymal programming while inhibiting tumor initiation. *Cancer Res.* **2015**, *75*, 1908–1921. [[CrossRef](#)] [[PubMed](#)]
165. Wiklund, E.D.; Bramsen, J.B.; Hulf, T.; Dyrskjot, L.; Ramanathan, R.; Hansen, T.B.; Villadsen, S.B.; Gao, S.; Ostenfeld, M.S.; Borre, M.; *et al.* Coordinated epigenetic repression of the mir-200 family and mir-205 in invasive bladder cancer. *Int. J. Cancer.* **2011**, *128*, 1327–1334. [[CrossRef](#)] [[PubMed](#)]
166. Chang, C.J.; Hsu, C.C.; Chang, C.H.; Tsai, L.L.; Chang, Y.C.; Lu, S.W.; Yu, C.H.; Huang, H.S.; Wang, J.J.; Tsai, C.H.; *et al.* Let-7d functions as novel regulator of epithelial-mesenchymal transition and chemoresistant property in oral cancer. *Oncol. Rep.* **2011**, *26*, 1003–1010. [[PubMed](#)]
167. Haga, C.L.; Phinney, D.G. Micrnas in the imprinted dlk1-dio3 region repress the epithelial-to-mesenchymal transition by targeting the twist1 protein signaling network. *J. Biol. Chem.* **2012**, *287*, 42695–42707. [[CrossRef](#)] [[PubMed](#)]
168. Nairismagi, M.L.; Vislovukh, A.; Meng, Q.; Kratassiouk, G.; Beldiman, C.; Petretich, M.; Groisman, R.; Fuchtbauer, E.M.; Harel-Bellan, A.; Groisman, I. Translational control of twist1 expression in mcf-10a cell lines recapitulating breast cancer progression. *Oncogene* **2012**, *31*, 4960–4966. [[CrossRef](#)] [[PubMed](#)]
169. Nairismagi, M.L.; Fuchtbauer, A.; Labouriau, R.; Bramsen, J.B.; Fuchtbauer, E.M. The proto-oncogene twist1 is regulated by micrnas. *PLoS ONE* **2013**, *8*, e66070. [[CrossRef](#)] [[PubMed](#)]
170. Li, L.Z.; Zhang, C.Z.; Liu, L.L.; Yi, C.; Lu, S.X.; Zhou, X.; Zhang, Z.J.; Peng, Y.H.; Yang, Y.Z.; Yun, J.P. Mir-720 inhibits tumor invasion and migration in breast cancer by targeting twist1. *Carcinogenesis* **2014**, *35*, 469–478. [[CrossRef](#)] [[PubMed](#)]
171. Hernandez, J.M.; Elahi, A.; Clark, C.W.; Wang, J.; Humphries, L.A.; Centeno, B.; Bloom, G.; Fuchs, B.C.; Yeatman, T.; Shibata, D. Mir-675 mediates downregulation of twist1 and rb in afp-secreting hepatocellular carcinoma. *Ann. Surg. Oncol.* **2013**, *20*, S625–S635. [[CrossRef](#)] [[PubMed](#)]
172. Tsukerman, P.; Yamin, R.; Seidel, E.; Khawaled, S.; Schmiedel, D.; Bar-Mag, T.; Mandelboim, O. Mir-520d-5p directly targets twist1 and downregulates the metastamir mir-10b. *Oncotarget* **2014**, *5*, 12141–12150. [[CrossRef](#)] [[PubMed](#)]
173. Liu, S.; Cui, J.; Liao, G.; Zhang, Y.; Ye, K.; Lu, T.; Qi, J.; Wan, G. Mir-137 regulates epithelial-mesenchymal transition in gastrointestinal stromal tumor. *Tumour Biol.* **2014**, *35*, 9131–9138. [[CrossRef](#)] [[PubMed](#)]
174. Zhou, Y.; Huang, Z.; Wu, S.; Zang, X.; Liu, M.; Shi, J. Mir-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating twist. *J. Exp. Clin. Cancer Res.* **2014**, *33*, 12. [[CrossRef](#)] [[PubMed](#)]
175. Yang, L.; Yang, J.; Li, J.; Shen, X.; Le, Y.; Zhou, C.; Wang, S.; Zhang, S.; Xu, D.; Gong, Z. Mircorna-33a inhibits epithelial-to-mesenchymal transition and metastasis and could be a prognostic marker in non-small cell lung cancer. *Sci. Rep.* **2015**, *5*, 13677. [[CrossRef](#)] [[PubMed](#)]
176. Zhu, X.; Shen, H.; Yin, X.; Long, L.; Xie, C.; Liu, Y.; Hui, L.; Lin, X.; Fang, Y.; Cao, Y.; *et al.* Mir-186 regulation of twist1 and ovarian cancer sensitivity to cisplatin. *Oncogene* **2015**.
177. Chang, Y.S.; Chen, W.Y.; Yin, J.J.; Sheppard-Tillman, H.; Huang, J.; Liu, Y.N. Egf receptor promotes prostate cancer bone metastasis by downregulating mir-1 and activating twist1. *Cancer Res.* **2015**, *75*, 3077–3086. [[CrossRef](#)] [[PubMed](#)]
178. Mani, S.A.; Guo, W.; Liao, M.J.; Eaton, E.N.; Ayyanan, A.; Zhou, A.Y.; Brooks, M.; Reinhard, F.; Zhang, C.C.; Shipitsin, M.; *et al.* The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell* **2008**, *133*, 704–715. [[CrossRef](#)] [[PubMed](#)]
179. Morel, A.P.; Lievre, M.; Thomas, C.; Hinkal, G.; Ansieau, S.; Puisieux, A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. *PLoS ONE* **2008**, *3*, e2888. [[CrossRef](#)] [[PubMed](#)]

180. Wellner, U.; Schubert, J.; Burk, U.C.; Schmalhofer, O.; Zhu, F.; Sonntag, A.; Waldvogel, B.; Vannier, C.; Darling, D.; zur Hausen, A.; *et al.* The emt-activator zeb1 promotes tumorigenicity by repressing stemness-inhibiting micrnas. *Nat. Cell. Biol.* **2009**, *11*, 1487–1495. [[CrossRef](#)] [[PubMed](#)]
181. Schepers, G.E.; Teasdale, R.D.; Koopman, P. Twenty pairs of sox: Extent, homology, and nomenclature of the mouse and human sox transcription factor gene families. *Dev. Cell* **2002**, *3*, 167–170. [[CrossRef](#)]
182. Stolt, C.C.; Wegner, M. Sox function in vertebrate nervous system development. *Int. J. Biochem. Cell. Biol.* **2010**, *42*, 437–440. [[CrossRef](#)] [[PubMed](#)]
183. Guth, S.I.; Bosl, M.R.; Sock, E.; Wegner, M. Evolutionary conserved sequence elements with embryonic enhancer activity in the vicinity of the mammalian sox8 gene. *Int. J. Biochem. Cell. Biol.* **2010**, *42*, 465–471. [[CrossRef](#)] [[PubMed](#)]
184. Wegner, M. All purpose sox: The many roles of sox proteins in gene expression. *Int. J. Biochem. Cell. Biol.* **2010**, *42*, 381–390. [[CrossRef](#)] [[PubMed](#)]
185. Sakai, D.; Suzuki, T.; Osumi, N.; Wakamatsu, Y. Cooperative action of sox9, snail2 and pka signaling in early neural crest development. *Development* **2006**, *133*, 1323–1333. [[CrossRef](#)] [[PubMed](#)]
186. Suske, G.; Bruford, E.; Philipsen, S. Mammalian sp/klf transcription factors: Bring in the family. *Genomics* **2005**, *85*, 551–556. [[CrossRef](#)] [[PubMed](#)]
187. Pearson, R.; Fleetwood, J.; Eaton, S.; Crossley, M.; Bao, S. Kruppel-like transcription factors: A functional family. *Int. J. Biochem. Cell. Biol.* **2008**, *40*, 1996–2001. [[CrossRef](#)] [[PubMed](#)]
188. Chambers, I.; Colby, D.; Robertson, M.; Nichols, J.; Lee, S.; Tweedie, S.; Smith, A. Functional expression cloning of nanog, a pluripotency sustaining factor in embryonic stem cells. *Cell* **2003**, *113*, 643–655. [[CrossRef](#)]
189. Sureban, S.M.; May, R.; Qu, D.; Weygant, N.; Chandrakesan, P.; Ali, N.; Lightfoot, S.A.; Pantazis, P.; Rao, C.V.; Postier, R.G.; *et al.* Dclk1 regulates pluripotency and angiogenic factors via microrna-dependent mechanisms in pancreatic cancer. *PLoS One* **2013**, *8*, e73940. [[CrossRef](#)] [[PubMed](#)]
190. Sureban, S.M.; May, R.; Weygant, N.; Qu, D.; Chandrakesan, P.; Bannerman-Menson, E.; Ali, N.; Pantazis, P.; Westphalen, C.B.; Wang, T.C.; *et al.* Xmd8-92 inhibits pancreatic tumor xenograft growth via a dclk1-dependent mechanism. *Cancer Lett.* **2014**, *351*, 151–161. [[CrossRef](#)] [[PubMed](#)]
191. Xia, Y.; Wu, Y.; Liu, B.; Wang, P.; Chen, Y. Downregulation of mir-638 promotes invasion and proliferation by regulating sox2 and induces emt in nslc. *FEBS Lett.* **2014**, *588*, 2238–2245. [[CrossRef](#)] [[PubMed](#)]
192. Chan, K.C.; Chan, L.S.; Ip, J.C.; Lo, C.; Yip, T.T.; Ngan, R.K.; Wong, R.N.; Lo, K.W.; Ng, W.T.; Lee, A.W.; *et al.* Therapeutic targeting of cbp/beta-catenin signaling reduces cancer stem-like population and synergistically suppresses growth of ebv-positive nasopharyngeal carcinoma cells with cisplatin. *Sci. Rep.* **2015**, *5*, 9979. [[CrossRef](#)] [[PubMed](#)]
193. Li, Y.; Lv, Z.; He, G.; Wang, J.; Zhang, X.; Lu, G.; Ren, X.; Wang, F.; Zhu, X.; Ding, Y.; *et al.* The sox17/mir-371-5p/sox2 axis inhibits emt, stem cell properties and metastasis in colorectal cancer. *Oncotarget* **2015**, *6*, 9099–9112. [[CrossRef](#)] [[PubMed](#)]
194. Zhou, A.D.; Diao, L.T.; Xu, H.; Xiao, Z.D.; Li, J.H.; Zhou, H.; Qu, L.H. Beta-catenin/lef1 transactivates the microrna-371-373 cluster that modulates the wnt/beta-catenin-signaling pathway. *Oncogene* **2012**, *31*, 2968–2978. [[CrossRef](#)] [[PubMed](#)]
195. Hahn, S.; Hermeking, H. Znf281/zbp-99: A new player in epithelial-mesenchymal transition, stemness, and cancer. *J. Mol. Med. (Berl.)* **2014**, *92*, 571–581. [[CrossRef](#)] [[PubMed](#)]
196. Ocana, O.H.; Corcoles, R.; Fabra, A.; Moreno-Bueno, G.; Acloque, H.; Vega, S.; Barrallo-Gimeno, A.; Cano, A.; Nieto, M.A. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer prrx1. *Cancer Cell* **2012**, *22*, 709–724. [[CrossRef](#)] [[PubMed](#)]
197. Zhang, Y.; Zheng, L.; Huang, J.; Gao, F.; Lin, X.; He, L.; Li, D.; Li, Z.; Ding, Y.; Chen, L. Mir-124 radiosensitizes human colorectal cancer cells by targeting prrx1. *PLoS ONE* **2014**, *9*, e93917. [[CrossRef](#)] [[PubMed](#)]
198. Xiang, X.; Zhuang, X.; Ju, S.; Zhang, S.; Jiang, H.; Mu, J.; Zhang, L.; Miller, D.; Grizzle, W.; Zhang, H.G. Mir-155 promotes macroscopic tumor formation yet inhibits tumor dissemination from mammary fat pads to the lung by preventing emt. *Oncogene* **2011**, *30*, 3440–3453. [[CrossRef](#)] [[PubMed](#)]

